Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Avacta Affimer Innovative Immunotherapies Presentation February 2019 https://www.***************************/avacta-affimer-innovative-immunotherapies-presentation-february-2019/412767326
From Nobbygnome on ADVFN- Very interesting presentations today, plus I had some good one to one discussions with the management and speakers. Will write up a summary later. The bottom line is that the were strong hints moe deals are coming in the short term so I won't be selling! Nobby
I’m new in today as an investment in a company that’s market cap is half a million pound, they have generated 30% of that in revenues in the first 6 weeks of 2019, I see this as a value long term play. Let the traders trade and move on
Avacta Group PLC Moderna Exercises Exclusive Product License Option Source: UK Regulatory (RNS & others) TIDMAVCT RNS Number : 9010O Avacta Group PLC 04 February 2019 4 February 2019 Avacta Group plc ("Avacta", the "Group" or the "Company") Moderna Exercises Option for an Exclusive Product License Avacta Group plc (AIM: AVCT), the developer of Affimer(R) biotherapeutics and reagents, is pleased to announce that ModernaTX, Inc. (NASDAQ: MRNA) has exercised its option to enter into an exclusive licensing agreement with respect to certain Affimers against a potential therapeutic target that has been part of an ongoing research collaboration between the two companies. In 2015, Avacta and Moderna entered into a collaboration, license and option agreement under which Moderna was granted exclusive access to Avacta's Affimer technology for certain collaboration targets and the option to enter into exclusive license agreements on pre-agreed terms to further research, develop and commercialize Affimers selected by Moderna. Under the terms of the agreement Avacta may receive undisclosed payments upon future clinical development milestones and royalties in connection with future product sales. Dr Alastair Smith, Avacta Group Chief Executive Officer, commented: "I am delighted to report that Moderna has exercised its option to enter into this exclusive license agreement with respect to certain Affimer molecules that have been generated through our collaboration. This is further strong validation of the potential of the Affimer drug platform to generate differentiated therapeutic molecules for development. We will continue to support Moderna and their development objectives and I look forward to updating the market as and when key development milestones are met." -Ends - For further information from Avacta Group plc, please contact: Avacta Group plc Tel: +44 (0) 844 414 0452 Alastair Smith, Chief Executive www.avacta.com Officer Tony Gardiner, Chief Financial Officer finnCap Ltd Tel: +44 (0) 207 220 0500 Geoff Nash / Giles Rolls - Nominated www.finncap.com Adviser Tim Redfern - ECM Tel: +44 (0) 203 705 9318 WG Partners Tel: +44 (0) 203 705 9217 Nigel Birks / Nigel Barnes www.wgpartners.co.uk David Wilson / Claes Spang Turner Pope Investments Tel: 020 3621 4120 James Pope www.turnerpope.com Ben Turner Zyme Communications (Trade and Regional Tel: +44 (0)7787 502 947 Media) katie.odgaard@zymecommunications.com Katie Odgaard Yellow Jersey (Financial Media and Tel: +44 (0)7764 947137 IR) Tel